InsiderDirector
Christopher Gibson Insider Trading Activity
Every SEC Form 4 transaction reported by Christopher Gibson, sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Is Christopher Gibson buying or selling?
Christopher Gibson reported 0 open-market buys ($0) and 76 sells ($39.6M) across 76 Form 4 filings at 1 company — a net selling position of $39.6M.
Source: SEC EDGAR Form 4
Key Statistics (as of Jun 5, 2026)
Total Form 4 filings
76
SEC EDGAR
Companies
1
Buys (0)
$0
Sells (76)
$39.6M
Insider sentiment
Net sellingNet insider flow of $39.6M in net selling, filed between Dec 10, 2021 – Jun 5, 2026.
Companies Christopher Gibson files for
| # | Company | Form 4 filings |
|---|---|---|
| 1 | RXRXRECURSION PHARMACEUTICALS, INC. | 76 |
Recent Christopher Gibson transactions
| Date | Ticker | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Jun 5, 2026 | RXRX | Director | Sale | 40.0K | $144.8K |
| May 27, 2026 | RXRX | Director | Sale | 40.0K | $123.2K |
| May 8, 2026 | RXRX | Director | Sale | 40.0K | $134.8K |
| Apr 24, 2026 | RXRX | Director | Sale | 40.0K | $144.4K |
| Apr 8, 2026 | RXRX | Director | Sale | 40.0K | $124.0K |
| Mar 25, 2026 | RXRX | Director | Sale | 40.0K | $130.0K |
| Feb 20, 2026 | RXRX | Director | Sale | 40.0K | $138.4K |
| Feb 6, 2026 | RXRX | Director | Sale | 40.0K | $164.8K |
| Jan 23, 2026 | RXRX | Director | Sale | 40.0K | $178.8K |
| Jan 7, 2026 | RXRX | Director | Sale | 40.0K | $170.0K |
| Dec 19, 2025 | RXRX | Chief Executive Officer | Sale | 40.0K | $180.0K |
| Dec 6, 2025 | RXRX | Chief Executive Officer | Sale | 40.0K | $185.2K |
| Nov 20, 2025 | RXRX | Chief Executive Officer | Sale | 40.0K | $166.4K |
| Nov 6, 2025 | RXRX | Chief Executive Officer | Sale | 40.0K | $208.4K |
| Oct 24, 2025 | RXRX | Chief Executive Officer | Sale | 100.0K | $570.0K |
| Oct 10, 2025 | RXRX | Chief Executive Officer | Sale | 100.0K | $604.0K |
| Sep 26, 2025 | RXRX | Chief Executive Officer | Sale | 100.0K | $476.0K |
| Sep 12, 2025 | RXRX | Chief Executive Officer | Sale | 100.0K | $471.0K |
| Aug 29, 2025 | RXRX | Chief Executive Officer | Sale | 100.0K | $484.0K |
| Aug 14, 2025 | RXRX | Chief Executive Officer | Sale | 618.2K | $3.3M |
| Mar 28, 2025 | RXRX | Chief Executive Officer | Sale | 138.6K | $837.0K |
| Mar 7, 2025 | RXRX | Chief Executive Officer | Sale | 40.0K | $259.0K |
| Feb 7, 2025 | RXRX | Chief Executive Officer | Sale | 40.0K | $316.0K |
| Jan 13, 2025 | RXRX | Chief Executive Officer | Sale | 40.0K | $287.2K |
| Dec 6, 2024 | RXRX | Chief Executive Officer | Sale | 40.0K | $285.6K |
Showing the 25 most recent filings of 76. Screen every filing.
Christopher Gibson insider trading FAQ
Is Christopher Gibson buying or selling?
Across 76 SEC Form 4 filings, Christopher Gibson reported 0 open-market purchases totaling $0 and 76 sales totaling $39.6M — a net selling position of $39.6M.
Which companies does Christopher Gibson file Form 4s for?
Christopher Gibson has reported insider transactions at 1 company, most often RECURSION PHARMACEUTICALS, INC. (RXRX).
How far back does Christopher Gibson's filing history go?
Trabud holds Christopher Gibson's SEC Form 4 filings from Dec 10, 2021 – Jun 5, 2026, sourced directly from SEC EDGAR.
Where does Trabud get Christopher Gibson's insider trading data?
Directly from SEC EDGAR Form 4 filings. Every transaction on this page is a real filing accepted by the SEC, updated as new filings arrive.
Related Content
Track Christopher Gibson and every other insider
Screen all SEC Form 4 filings by insider, company, transaction value, and role — or ask Trabud's AI agent in plain English.
Open the screener